Investors & Media
Dedicated to delivering long-term investment value.
Featured News: CSL and uniQure Win 2023 Prix Galien USA Award
At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.
Subscribe to receive breaking news alerts about uniQure.Subscribe
Updated stock ticker information for uniQure
(Updated every 15 minutes)
Security and exchange commission filings for uniQure, including quarterly and annual reportsLearn More
Links to key uniQure corporate governance documentsLearn More
No webcasts scheduled. Check back soon.
Huntington's Disease Program Update AMT-130 – Webcast PresentationView Presentation
Virtual Research & Development Event – Nov. 29 event focused on preclinical gene therapy candidate for refractory temporal lobe epilepsy (rTLE) AMT-260 and uniQure AAV manufacturing advancementsView Presentation
ESGCT 2022 – Enhancing efficacy and specificity of AAV5 capsid via small, intermediate, and large peptide insertionsView Presentation
EAHAD 2022 – Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderately Severe Hemophilia BView Presentation
ESGCT 2022 – linQURE™ platform: Development of novel scaffolds for multi-transcript targeting towards the treatment of complex genetic disordersView Presentation